Royal Bank Of Canada Downgrades Sandoz Group (OTCMKTS:SDZNY) to Hold

Sandoz Group (OTCMKTS:SDZNY) was downgraded by stock analysts at Royal Bank Of Canada from a “moderate buy” rating to a “hold” rating in a research report issued on Monday,Zacks.com reports.

Several other research firms have also recently issued reports on SDZNY. Barclays cut Sandoz Group from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 26th. Jefferies Financial Group raised Sandoz Group from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

Sandoz Group Stock Performance

OTCMKTS:SDZNY opened at $75.94 on Monday. The company has a current ratio of 1.29, a quick ratio of 0.82 and a debt-to-equity ratio of 0.62. The company’s 50 day moving average price is $81.52 and its 200-day moving average price is $71.92. Sandoz Group has a 52 week low of $35.61 and a 52 week high of $94.15.

About Sandoz Group

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.